European Union to Provide 88 Million COVID-19 Vaccine Doses for Poor Countries

Andrew Cummings
September 20, 2020

AstraZeneca had to temporarily put on hold the phase-3 trial on AZD1222, a vaccine candidate in development jointly with Oxford University, to review an adverse reaction. The company also announced that it is planning to produce roughly 20M doses of its vaccine candidate, mRNA-1273, this year.

President von der Leyen said: "With today's contract with Sanofi-GSK, the European Commission shows once again its commitment to ensuring equitable access to safe, effective and affordable vaccines not only for its citizens but also for the world's poorest and most vulnerable people". Trump did not specify which vaccine effort he believed would be cleared by the US Food and Drug Administration.

The most important of these is how it will judge whether results are conclusive.

"If the infection rate in the country were to slow down in the next weeks, it could potentially be pushed out in a worst-case scenario in December", he added. Some volunteers have already come forward for the trial. It will be part of the European Union efforts to secure a global equitable distribution of the latest coronavirus vaccine.


Interim analyses by a committee of independent experts are planned over the course of the trial to verify whether a high statistical threshold of effectiveness has been reached, and to monitor for serious side effects.

As reported, Murashko said that the symptoms after being injected with the Russian COVID-19 vaccine "level off" by the next day and the complications are "described in the instructions and are predictable".

Moderna has disclosed the information on enrollment on the phase-3 COVE trial on Thursday.

Having sufficient participants among black and Hispanic people in particular is crucial in obtaining statistically representative results for these communities that have been disproportionately hit by the pandemic.


The company's latest news release detailed that, as of September 16, the "Phase 3 COVE [Coronavirus Efficacy] study" has enrolled 25,296 participants out of the total 30,000 volunteers needed.

The decision by Moderna, which has received $2.5 billion in USA government money, left a spotlight on Pfizer, whose CEO has repeatedly said the company will have its results by the end of October, which is in line with Trump's wishes.

The other frontrunner is AstraZeneca, which has codeveloped a vaccine with the University of Oxford. Novavax, which is expected to start a large, advanced clinical trial later this year, also did not comment.

The US remains the exception for reasons that aren't yet known.


Other reports by iNewsToday

FOLLOW OUR NEWSPAPER